Nasus Pharma (NYSEAMERICAN:NSRX) CEO Dan Benjamin Teleman Purchases 2,900 Shares of Stock

Nasus Pharma Ltd. (NYSEAMERICAN:NSRX) CEO Dan Benjamin Teleman purchased 2,900 shares of Nasus Pharma stock in a transaction on Wednesday, April 22nd. The stock was bought at an average price of $3.76 per share, with a total value of $10,904.00. Following the completion of the acquisition, the chief executive officer directly owned 156,991 shares of the company’s stock, valued at approximately $590,286.16. This trade represents a 1.88% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Nasus Pharma Trading Down 12.6%

Shares of NYSEAMERICAN NSRX opened at $3.40 on Friday. The firm’s 50-day moving average is $3.60. Nasus Pharma Ltd. has a 1-year low of $1.98 and a 1-year high of $9.99.

Analysts Set New Price Targets

Separately, Citizens Jmp dropped their price target on Nasus Pharma from $19.00 to $18.00 and set a “market outperform” rating on the stock in a research note on Thursday, March 26th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $18.00.

About Nasus Pharma

Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions. Nasus Pharma Ltd. is based in TEL AVIV, Israel.